The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel

The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel

Abstract Introduction Psoriasis is a chronic inflammatory condition affecting the skin, joints, and several other organ systems with significant disease burden. Bimekizumab is the first monoclonal antibody targeting both interleukin (IL)-17A and interleukin-17F and has demonstrated efficacy for trea...

Full description

Bibliographic Details
Main Authors: Joshua Burshtein, Milaan Shah, Danny Zakria, Benjamin Lockshin, Jeff Crowley, Joseph F. Merola, Ken Gordon, Mona Shahriari, Neil J. Korman, Raj Chovatiya, Robert Kalb, Mark Lebwohl
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-02-01
Series:Dermatology and Therapy
Subjects:
Psoriasis
IL-17
Interleukin
Biologic
Bimekizumab
Treatment
Online Access:https://doi.org/10.1007/s13555-024-01099-y

Internet

https://doi.org/10.1007/s13555-024-01099-y

Similar Items